News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Trump Ends Government Shutdown; Software Stocks Hit by AI Tools; Nvidia Plans Massive Investment in OpenAI (February 4, 2026)2BitMine adds 41,000 ETH to its balance sheet, while its unrealized losses amount to $6B3XRP price prediction: What the loss of the $1.77 swing low means for you
Billionaire Backers Expected to Present Hurdles for Incoming OCBC CEO Tan
101 finance·2026/02/05 00:21
US Dollar: Changes Emerging in the US Stock Market
BFC汇谈·2026/02/05 00:02
Alphabet refuses to discuss the AI partnership between Google and Apple, even with its investors
101 finance·2026/02/04 23:51
Saks Off 5th to close most of its stores. Check which locations are affected.
101 finance·2026/02/04 23:39
American Superconductor (NASDAQ:AMSC) Posts Strong Q4 CY2025 Results, Shares Surge 19.7%
101 finance·2026/02/04 23:24
Dalio says gold remains the safest investment choice
新浪财经·2026/02/04 23:23
Flash
00:54
Galaxy Digital: Clients Sold About $9 Billion Worth of Bitcoin Not Due to "Quantum Computing Risks"According to Odaily, Alex Thorn, Head of Research at Galaxy Digital, stated that a recent sale of approximately $9 billion worth of bitcoin by a Galaxy client was not motivated by concerns over so-called "quantum computing risks." He pointed out that although Galaxy Digital founder and CEO Mike Novogratz had mentioned that some in the market view quantum computing as one of the explanations for bitcoin's price weakness, Novogratz himself does not agree with this view.
00:46
US Stocks Movement | Bomei Group drops 38.08%, becoming the largest decliner among Chinese concept stocksGlonghui, February 5th｜The Chinese concept stocks with the largest declines at the close were: Bomei Group down 38.08%, Liandai Technology down 33.65%, Huachen Technology down 21.29%, Huipusen Pharma down 19.99%, and MKDWELL Tech down 17.93%. (Glonghui)
00:45
Tirzepatide locks in the global "King of Drugs" title with $36.5 billion; Eli Lilly expects revenue to exceed $80 billion this yearGelonghui, February 5th｜The annual revenue of Eli Lilly's tirzepatide in 2025 will surpass Novo Nordisk's semaglutide, securing the global "King of Drugs" title for 2025 in advance. On February 4th local time, Eli Lilly (LLY.US) released its financial report for the fourth quarter of 2025 as well as the full year of 2025. The company's fourth-quarter revenue reached $19.29 billions, a year-on-year increase of 43%, exceeding analysts' expectations; total annual revenue reached $65.179 billions, a year-on-year increase of 44% at constant exchange rates (CER), and net profit was $20.64 billions, a year-on-year increase of 95%.
News